Percentage of expenses for co-promotion of sales and medical affairs.

No definition available.

Name:	mdvn_CoPromotionOfSalesAndMedicalAffairsPercentage
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Maximum dollar amount of milestone payments eligible to be received under a collaboration arrangement.

+ References

No definition available.

+ Details

Name:	mdvn_MaximumEligibleMilestonePaymentsUnderCollaborationArrangement
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Dollar amount of milestone payments earned to date pursuant to collaboration agreement.

+ References

No definition available.

+ Details

Name:	mdvn_MilestonePaymentsEarnedToDateUnderCollaborationAgreement
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of all Sublicensing Income, as defined in agreement, payable to licensor.

+ References

No definition available.

+ Details

Name:	mdvn_PercentageOfSublicensingIncome
Namespace Prefix:	mdvn_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Remaining milestone payments that are eligible to be received in the future under collaboration arrangements.

+ References

No definition available.

+ Details

Name:	mdvn_RemainingFutureMilestonePaymentsEligibleToReceiveUnderCollaborationArrangements
Namespace Prefix:	mdvn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Range of percentage rates for royalties received on ex-U.S. sales, as defined by collaboration agreement.

+ References

No definition available.

+ Details

Name:	mdvn_RoyaltiesAtPercentageRatesRanging
Namespace Prefix:	mdvn_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Collaboration Agreement - Collaboration Agreements with Astellas - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	9 Months Ended		3 Months Ended	9 Months Ended	1 Months Ended	9 Months Ended
	Sep. 30, 2014 Collaborative agreement [Member]	Sep. 30, 2014 Astellas Pharma Inc. [Member] Collaborative agreement [Member]	Dec. 31, 2009 Upfront cash payment arrangement [Member] Astellas Pharma Inc. [Member]	Sep. 30, 2014 Development milestone payments [Member] Astellas Pharma Inc. [Member]	Oct. 31, 2014 Development milestone payments [Member] Astellas Pharma Inc. [Member] Subsequent Event [Member]	Sep. 30, 2014 Sales milestone payments [Member] Astellas Pharma Inc. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Co-promotion of sales and medical affairs percentage	50.00%
Royalty received on ex-U.S. sales per collaboration arrangement		Low teens to the low twenties
Non-refundable, upfront cash payment			$ 110.0
Eligible to receive milestone payments				335.0		320.0
Milestone payments earned				245.0		25.0
Remaining future milestone payments eligible to receive				$ 90.0	$ 45.0	$ 295.0
Percentage of sublicensing income				10.00%